AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32856211 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune-suppressive therapy
Number of subjects: 0
Study 32856211 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid treatment
Number of subjects: 0
Study 34849918 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5mg/kg of etrolizumab subcutaneously every 4 weeks (q4w)
Number of subjects: 24
Study 34849918 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.0mg/kg of etrolizumab subcutaneously every 8 weeks (q8w)
Number of subjects: 24
Study 34849918 — intervention group
Group type: EXPERIMENTAL
Intervention: Both dosing regimens of etrolizumab
Number of subjects: 24
Study 34591808 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral dual TAP (BD‐TAP) block with multimodal analgesia under general anesthesia using 0.25% ropivacaine
Number of subjects: 76
Study 34591808 — intervention group
Group type: COMPARATOR
Intervention: Sham block using 0.9% normal saline with the same multimodal analgesia regimen
Number of subjects: 76
Study 36468650 — intervention group
Group type: EXPERIMENTAL
Intervention: CBTp (Cognitive Behavioral Therapy for parasomnias)
Number of subjects: 19
Study 36468650 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring control
Number of subjects: 19
Study 36468650 — intervention group
Group type: EXPERIMENTAL
Intervention: CBTp
Number of subjects: 19
Study 33360967 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinatorial pharmacogenomic test
Number of subjects: 1022
Study 33360967 — intervention group
Group type: COMPARATOR
Intervention: Single-gene guidelines
Number of subjects: 1022
Study 33360967 — intervention group
Group type: COMPARATOR
Intervention: Combinatorial pharmacogenomic test and single-gene guidelines
Number of subjects: 1022
Study 34111277 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 731
Study 34111277 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 731
Study 34111277 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 731
Study 32503556 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol (800mcg sublingual for treatment, 600mcg oral for prophylaxis)
Number of subjects: 1884
Study 32503556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1884
Study 32503556 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 1884
Study 33591003 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission hemoglobin levels
Number of subjects: 4172
Study 33063323 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflectance Confocal Microscopy (RCM)
Number of subjects: 0
Study 33063323 — intervention group
Group type: COMPARATOR
Intervention: Dermatoscopic evaluation
Number of subjects: 0
Study 36064720 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Tuina
Number of subjects: 176
Study 36064720 — intervention group
Group type: COMPARATOR
Intervention: Medilac‐Vita
Number of subjects: 176
Study 34878933 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Therapy (LT) (808 nm, 100 mW, 40 sec/point, 4 J/point, intra/extraoral)
Number of subjects: 60
Study 34878933 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Acupuncture (LA) (same parameters as LT, applied at six acupuncture points)
Number of subjects: 60
Study 34878933 — intervention group
Group type: COMPARATOR
Intervention: Control (systemic medication - ETNA®, 01 capsule, 8/8 h, 30 days)
Number of subjects: 60
Study 34092654 — intervention group
Group type: EXPERIMENTAL
Intervention: PD03A 15μg
Number of subjects: 36
Study 34092654 — intervention group
Group type: EXPERIMENTAL
Intervention: PD03A 75μg
Number of subjects: 36
Study 34092654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 34092654 — intervention group
Group type: EXPERIMENTAL
Intervention: PD03A 15μg and PD03A 75μg
Number of subjects: 36
Study 33216013 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) group program PROTECT+, 4 sessions
Number of subjects: 54
Study 33280041 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (600 IU/day)
Number of subjects: 221
Study 33280041 — intervention group
Group type: COMPARATOR
Intervention: Vitamin D3 supplementation (3750 IU/day)
Number of subjects: 221
Study 33280041 — intervention group
Group type: EXPERIMENTAL
Intervention: Total 25(OH)D
Number of subjects: 221
Study 33280041 — intervention group
Group type: EXPERIMENTAL
Intervention: Free and bioavailable 25(OH)D
Number of subjects: 221
Study 33280041 — intervention group
Group type: EXPERIMENTAL
Intervention: All vitamin D variables
Number of subjects: 221
Study 33280041 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and bone turnover markers
Number of subjects: 221
Study 33280041 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated free and bioavailable 25(OH)D
Number of subjects: 221
Study 32627474 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhibitai Capsules combined with statins
Number of subjects: 1538
Study 32627474 — intervention group
Group type: COMPARATOR
Intervention: Statins alone
Number of subjects: 1538
Study 34120195 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-bone fixation
Number of subjects: 50
Study 34120195 — intervention group
Group type: COMPARATOR
Intervention: Both-bone fixation
Number of subjects: 50
Study 34749008 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month health coach intervention combined with usual oncology care
Number of subjects: 0
Study 34749008 — intervention group
Group type: COMPARATOR
Intervention: Usual oncology care alone
Number of subjects: 0
Study 32268027 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoid injection
Number of subjects: 156
Study 32268027 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 156
Study 35469777 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach Contact plus Decision Counseling (OC-DC)
Number of subjects: 2376
Study 35469777 — intervention group
Group type: EXPERIMENTAL
Intervention: Outreach Contact alone (OC)
Number of subjects: 2376
Study 35469777 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 2376
Study 33843315 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of healthy food choices
Number of subjects: 774
Study 33843315 — intervention group
Group type: EXPERIMENTAL
Intervention: Raising awareness of negative health consequences of excessive consumption of sugar, fat, and sodium
Number of subjects: 774
Study 33843315 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of informed food choices
Number of subjects: 774
Study 32573474 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional flap surgery with PRF
Number of subjects: 60
Study 32573474 — intervention group
Group type: COMPARATOR
Intervention: Conventional flap surgery (Control)
Number of subjects: 60
Study 36231494 — intervention group
Group type: EXPERIMENTAL
Intervention: ELLA training for the promotion of emotional and social competences
Number of subjects: 140
Study 36231494 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 140
Study 32871952 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA-146b-3p
Number of subjects: 506
Study 32871952 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNA-363–3p
Number of subjects: 506
Study 32871952 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score based on miRNA-146b-3p and miRNA-363–3p
Number of subjects: 506
Study 35040506 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus (2-6 mg daily) for 48 weeks
Number of subjects: 47
Study 35040506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 32131912 — intervention group
Group type: EXPERIMENTAL
Intervention: ZuraGard, a 2% chlorhexidine/70% isopropyl alcohol preparation
Number of subjects: 3277
Study 32131912 — intervention group
Group type: COMPARATOR
Intervention: Chloraprep (control)
Number of subjects: 3277
Study 32131912 — intervention group
Group type: EXPERIMENTAL
Intervention: ZuraGard
Number of subjects: 3277
Study 32131912 — intervention group
Group type: COMPARATOR
Intervention: Chloraprep
Number of subjects: 3277
Study 35977053 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM-guided transfusion strategy
Number of subjects: 60
Study 35977053 — intervention group
Group type: COMPARATOR
Intervention: Conventional transfusion strategy
Number of subjects: 60
Study 32925421 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia-based patient counseling (video education)
Number of subjects: 98
Study 32925421 — intervention group
Group type: COMPARATOR
Intervention: Traditional conversation-based patient counseling (control group)
Number of subjects: 98
Study 35882375 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral carbohydrate (OC group) - 300 mL/bottle
Number of subjects: 112
Study 35882375 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo (OP group) - 300 mL distilled water
Number of subjects: 112
Study 35882375 — intervention group
Group type: COMPARATOR
Intervention: Control group (C group) - forbidden from drinking or eating
Number of subjects: 112
Study 34854808 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary trabeculectomy treatment - trabeculectomy augmented with mitomycin C
Number of subjects: 453
Study 34854808 — intervention group
Group type: COMPARATOR
Intervention: Primary medical treatment - escalating medical management with glaucoma eye drops
Number of subjects: 453
Study 33274689 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban combined with heparin
Number of subjects: 98
Study 33274689 — intervention group
Group type: COMPARATOR
Intervention: Aspirin + clopidogrel
Number of subjects: 98
Study 33049730 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% oxygen at 10 l/min until delivery
Number of subjects: 117
Study 33049730 — intervention group
Group type: COMPARATOR
Intervention: Conventional care without additional oxygen
Number of subjects: 117
Study 35068016 — intervention group
Group type: EXPERIMENTAL
Intervention: Shaker head-lift exercise (HLE)
Number of subjects: 52
Study 35068016 — intervention group
Group type: COMPARATOR
Intervention: Standard dysphagia management (control)
Number of subjects: 52
Study 34687435 — intervention group
Group type: EXPERIMENTAL
Intervention: Copaiba oil in silicone gel, applied twice a day for 84 days
Number of subjects: 42
Study 34687435 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel, applied twice a day for 84 days
Number of subjects: 42
Study 32632523 — intervention group
Group type: EXPERIMENTAL
Intervention: surgical mask (sm)
Number of subjects: 12
Study 32632523 — intervention group
Group type: EXPERIMENTAL
Intervention: FFP2/N95 mask (ffpm)
Number of subjects: 12
Study 32632523 — intervention group
Group type: COMPARATOR
Intervention: no mask (nm)
Number of subjects: 12
Study 36160864 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (375 mg/d)
Number of subjects: 45
Study 36160864 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 33576219 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin gel (Curenext)
Number of subjects: 60
Study 33576219 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe Vera gel (Aloe Vera 100% relief)
Number of subjects: 60
Study 35248428 — intervention group
Group type: EXPERIMENTAL
Intervention: Meek technique
Number of subjects: 40
Study 35248428 — intervention group
Group type: COMPARATOR
Intervention: meshed group
Number of subjects: 40
Study 33589582 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 200
Study 33589582 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure management
Number of subjects: 200
Study 33589582 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholesterol management
Number of subjects: 200
Study 33589582 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall therapeutic objectives
Number of subjects: 200
Study 36125473 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet noninvasive ventilation
Number of subjects: 320
Study 36125473 — intervention group
Group type: COMPARATOR
Intervention: Usual respiratory support
Number of subjects: 320
Study 33550706 — intervention group
Group type: COMPARATOR
Intervention: AHA diet
Number of subjects: 98
Study 33550706 — intervention group
Group type: COMPARATOR
Intervention: FLiO diet
Number of subjects: 98
Study 32166308 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + vorinostat
Number of subjects: 90
Study 32166308 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 90
Study 35717193 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (MDA) with efficient duration of delivery (within ten days)
Number of subjects: 360
Study 35717193 — intervention group
Group type: EXPERIMENTAL
Intervention: Various combinations of influential intervention components
Number of subjects: 360
Study 35717193 — intervention group
Group type: COMPARATOR
Intervention: No individual activity
Number of subjects: 360
Study 34914243 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (HM)
Number of subjects: 102
Study 34914243 — intervention group
Group type: COMPARATOR
Intervention: Low-dose dexmedetomidine + Hydromorphone (DM + HM)
Number of subjects: 102
Study 35961520 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (1500 mg intravenously) every 4 weeks for up to 24 months
Number of subjects: 117
Study 34788640 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior left pericardiotomy
Number of subjects: 420
Study 34788640 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 420
Study 35290183 — intervention group
Group type: EXPERIMENTAL
Intervention: Exo4Work exoskeleton
Number of subjects: 22
Study 32621383 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe acne patients
Number of subjects: 51
Study 32621383 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 51
Study 36042582 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electric pulse therapy (LFEPT) combined with tropisetron hydrochloride and dexamethasone hydrochloride
Number of subjects: 82
Study 36042582 — intervention group
Group type: COMPARATOR
Intervention: Control group with tropisetron hydrochloride and dexamethasone hydrochloride
Number of subjects: 82
Study 36042582 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electric pulse therapy (LFEPT)
Number of subjects: 82
Study 36042582 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 33417292 — intervention group
Group type: EXPERIMENTAL
Intervention: Henagliflozin 5 mg
Number of subjects: 468
Study 33417292 — intervention group
Group type: EXPERIMENTAL
Intervention: Henagliflozin 10 mg
Number of subjects: 468
Study 33417292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 34850605 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage before gavage feeding
Number of subjects: 120
Study 34850605 — intervention group
Group type: COMPARATOR
Intervention: Control group (no abdominal massage)
Number of subjects: 120
Study 34518147 — intervention group
Group type: COMPARATOR
Intervention: Water-based circuit training exercise (WEX)
Number of subjects: 52
Study 34518147 — intervention group
Group type: COMPARATOR
Intervention: Gym-based circuit training exercise (GEX)
Number of subjects: 52
Study 35220359 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT plus agomelatine 50 mg/d
Number of subjects: 97
Study 35220359 — intervention group
Group type: COMPARATOR
Intervention: ECT plus placebo
Number of subjects: 97
Study 35220359 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine 50 mg/d during follow-up
Number of subjects: 97
Study 33405474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical Advantage Tourniquet (MAT)
Number of subjects: 96
Study 33405474 — intervention group
Group type: COMPARATOR
Intervention: Combat Application Tourniquet (CAT)
Number of subjects: 96
Study 33405474 — intervention group
Group type: COMPARATOR
Intervention: Stretch Wrap and Tuck Tourniquet (SWATT)
Number of subjects: 96
Study 35030239 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum caffeine (T3 compared with T1)
Number of subjects: 1228
Study 35030239 — intervention group
Group type: EXPERIMENTAL
Intervention: Paraxanthine (T3 compared with T1)
Number of subjects: 1228
Study 35030239 — intervention group
Group type: EXPERIMENTAL
Intervention: Theobromine (T3 compared with T1)
Number of subjects: 1228
Study 35030239 — intervention group
Group type: EXPERIMENTAL
Intervention: Total caffeinated beverages (>3 compared with 0 servings/d)
Number of subjects: 1228
Study 35030239 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (>2 compared with 0 servings/d)
Number of subjects: 1228
Study 35030239 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated soda (>2 servings/d)
Number of subjects: 1228
Study 32371166 — intervention group
Group type: EXPERIMENTAL
Intervention: Telbivudine (LdT) during the third trimester
Number of subjects: 0
Study 34018430 — intervention group
Group type: EXPERIMENTAL
Intervention: Condensed (2 hours) version of a popular Swahili radio drama
Number of subjects: 1200
Study 35179082 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioural Therapy
Number of subjects: 465
Study 35179082 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Term Psychoanalytic Psychotherapy
Number of subjects: 465
Study 35179082 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Psychosocial Intervention
Number of subjects: 465
Study 35179082 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 465
Study 36410223 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion 75 mg twice daily for twelve weeks
Number of subjects: 64
Study 36410223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 33406087 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal impairment (MSI)
Number of subjects: 8801
Study 33406087 — intervention group
Group type: COMPARATOR
Intervention: No formal education
Number of subjects: 8801
Study 33406087 — intervention group
Group type: EXPERIMENTAL
Intervention: Congenital causes of MSI
Number of subjects: 8801
Study 33406087 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological causes of MSI
Number of subjects: 8801
Study 33406087 — intervention group
Group type: EXPERIMENTAL
Intervention: Acquired non-traumatic non-infective causes of MSI
Number of subjects: 8801
Study 33406087 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma-related causes of MSI
Number of subjects: 8801
Study 33406087 — intervention group
Group type: EXPERIMENTAL
Intervention: Infection-related causes of MSI
Number of subjects: 8801
Study 33406087 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measures using EQ-5D
Number of subjects: 8801
Study 32080103 — intervention group
Group type: EXPERIMENTAL
Intervention: Active photobiomodulation therapy with active electrical stimulation
Number of subjects: 144
Study 32080103 — intervention group
Group type: EXPERIMENTAL
Intervention: Active photobiomodulation therapy
Number of subjects: 144
Study 32080103 — intervention group
Group type: EXPERIMENTAL
Intervention: Active electrical stimulation
Number of subjects: 144
Study 32080103 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 144
Study 32080103 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 144
Study 36660969 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming 3 days a week for 6 weeks
Number of subjects: 24
Study 36660969 — intervention group
Group type: COMPARATOR
Intervention: Vestibular training 3 days a week for 6 weeks
Number of subjects: 24
Study 34188459 — intervention group
Group type: EXPERIMENTAL
Intervention: ICT-based multicomponent program applied twice per week, once per day for 12 weeks, 30 min per session
Number of subjects: 20
Study 34188459 — intervention group
Group type: COMPARATOR
Intervention: Usual daily activities (control group)
Number of subjects: 20
Study 32274890 — intervention group
Group type: EXPERIMENTAL
Intervention: iButton data logger system
Number of subjects: 25
Study 32274890 — intervention group
Group type: COMPARATOR
Intervention: Infrared pistol
Number of subjects: 25
Study 32274890 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin's perfusion of microcirculation
Number of subjects: 25
Study 36462798 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 50
Study 36462798 — intervention group
Group type: COMPARATOR
Intervention: Intercostal Nerve Block (ICNB)
Number of subjects: 50
Study 32987492 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoral (PEC II) block
Number of subjects: 60
Study 32987492 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus-intercostal fascial plane (SIFP) block
Number of subjects: 60
Study 32987492 — intervention group
Group type: COMPARATOR
Intervention: Control group (no block)
Number of subjects: 60
Study 34590538 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom Use Self-Efficacy Scale (CUSES)
Number of subjects: 79
Study 34581237 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous pushing with pursed lips breathing
Number of subjects: 62
Study 34581237 — intervention group
Group type: COMPARATOR
Intervention: Directed pushing associated with Valsalva Manoeuvre (VM)
Number of subjects: 62
Study 34029678 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-regulated interventions
Number of subjects: 549
Study 34029678 — intervention group
Group type: COMPARATOR
Intervention: Regulated interventions
Number of subjects: 549
Study 35044883 — intervention group
Group type: EXPERIMENTAL
Intervention: PALliatiVE approach (Prepare, Ask, Listen, Validate, Consult an Expert)
Number of subjects: 0
Study 32633217 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening (PM; 16:00 hr)
Number of subjects: 12
Study 32633217 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred time (PREF)
Number of subjects: 12
Study 36442484 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezafungin (400 mg in week 1, followed by 200 mg weekly, for a total of two to four doses)
Number of subjects: 199
Study 36442484 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin (70 mg loading dose on day 1, followed by 50 mg daily)
Number of subjects: 199
Study 36442484 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezafungin
Number of subjects: 199
Study 36442484 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin
Number of subjects: 199